Article
Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements.
Current oncology (Toronto, Ont.) - 14 Sept 2021
Thawer Alia, Miller Wilson H, Gregorio Nancy, Claveau Joël, Rajagopal Sudha, Savage Kerry J, Song Xinni, Petrella Teresa M, On Behalf Of The Canadian Working Group
Abstract excerpt
The combination of dabrafenib and trametinib is a well-established treatment for BRAF-mutated melanoma. However, the effectiveness of this approach may be hindered by the development of treatment-related pyrexia syndrome, which occurs in at least 50% of treated patients. Without appropriate intervention, pyrexia syndrome has the potential to worsen and can result in hypotension secondary to dehydration and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.